Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2011

View Archived Issues

Japanese scientists describe miRNAs in plasma and synovial fluid as biomarkers for RA and OA

AM-432 is active in models of inflammatory respiratory conditions

New prostanoid EP4 receptor antagonist MF-592 has promising preclinical profile

Activators of ERK signaling may provide new therapeutic approach for HD

Lapatinib plus capecitabine does not improve survival of patients with metastatic pancreatic cancer

Phase Ib trials assess drozitumab-based combination regimens in advanced mCRC

Gilead Sciences presents new antiviral compounds

Soligenix and University of Colorado enter agreement for thermostable vaccines

Eisai establishes subsidiary to develop next-generation cancer drugs

Novel agonists of cannabinoid CB1 and CB2 receptors disclosed

New adenosine A2B receptor antagonists claimed by PGxHealth

Bayer and Zydus Cadila form joint company in India to optimize product portfolios

Arena Pharma provides update on lorcaserin and its pipeline

Pathway Therapeutics divulges novel PI3K inhibitors

MorphoSys receives milestone payment from OncoMed Pharma for phase I OMP-59R5 trial

CSL Behring's Berinert approved in Israel for acute HAE

Pfizer issues milestone payment to MorphoSys regarding phase I testing of HuCAL-derived antibody

Antisoma discontinues development of AS-1413 in secondary AML

FDA approves Menveo vaccine for children but refuses sBLA for use in infants

Collaboration launched to develop biomarker predicting response to PF-01367338

Rituxan approved in U.S. for first-line maintenance use in follicular lymphoma

AMT receives grant to develop AMT-021 for acute intermittent porphyria

Verona Pharma seeks U.K. clearance for clinical trials of RPL-554

European Commission approves Johnson & Johnson's acquisition of Crucell

FDA approves Gralise for once-daily treatment of postherpetic neuralgia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...